Information Provided By:
Fly News Breaks for November 27, 2017
SPRO
Nov 27, 2017 | 07:17 EDT
BofA/Merrill analyst Tazeen Ahmad initiated Spero Therapeutics with a Neutral and $16 price target saying shares are close to full valuation.
News For SPRO From the Last 2 Days
There are no results for your query SPRO